LBA12_PRPERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results
| Image |  |
|---|---|
| Description | scholarly article by C Hulme et al published 1 October 2018 in Annals of Oncology |
| Author/s |
author: Per Hall |
| Publication date | October 1, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |